We randomly assigned ( @:@ ) patients ( stratified by HCV genotype @ subtype -LSB- @a plus other/@b -RSB- and previous treatment response -LSB- partial or null -RSB- ) to receive simeprevir ( @ mg once a day ) plus telaprevir placebo ( three times a day @-@ h apart ) or telaprevir ( @ mg three times a day ) plus simeprevir placebo ( once a day ) in combination with peginterferon alfa-@a and ribavirin for @ weeks followed by @ weeks of peginterferon alfa-@a and ribavirin alone .